Clinical trials: Cardiovascular Event
Ischemia, Cardiac Death
A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions
E.V.O.L.U.T.I.O.N.: A Randomized Study to Evaluate Safety and Efficacy of the Excel Sirolimus Eluting Stent with a Biodegradable Polymer Versus Sirolimus Eluting Stent with a Non-Biodegradable Polymer in the Treatment of Patients…
- Conditions
- Ischemia, Cardiac Death, Myocardial Infarction
- Trial name
- EVOLUTION (NCT00825773)
- Testing
- Percutaneous Transluminal Coronary Angioplasty
- Where
- China
- Volunteers
- 1,944 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease
Carotid Plaque Length to Predict Cardiovascular Events
This multicenter study involved 5 hospitals (Changhai Hospital; Yueyang Hospital of Shanghai University of Traditional Chinese Medicine; Gongli Hospital; Putuo Hospital of Shanghai University of Traditional Chinese Medicine; No.
- Trial name
- NCT05409209
- Where
- 5 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Changhai Hospital
Death, Myocardial Infarction
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events.
- Conditions
- Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
- Trial name
- TARGET-D (NCT02996721)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Intermountain Health Care, Inc.
Hematologic Disease, Hemophilia A
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule…
- Trial name
- NCT00586521
- Testing
- Kogenate (BAY14-2222)
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Bayer
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Myocardial Infarction, Acute
Cardiovascular Risk Assessment Model in Patients With MI
This study aims to investigate life-style and psycho social factors of major cardiovascular events in patients with myocardial infarction in three different provinces of Iran and to design a risk assessment chart for major…
- Trial name
- NCT03957005
- Where
- 4 sites in Iran
- Volunteers
- 2,000 people
- Sponsor
- Isfahan University of Medical Sciences
Atherosclerosis, Coronary, Diabetes Mellitus
Fat Around Heart Arteries as a Measure of Inflammation in Patients With Diabetes
In this prospective study, the objective is to investigate inflammation in the arteries of the heart. A heart CT scan (CCTA) will be used to measure inflammation by assessing the fat tissue surrounding the arteries of the heart.
- Conditions
- Atherosclerosis, Coronary, Diabetes Mellitus, Diabetes Mellitus Type 2, Inflammation
- Trial name
- PCAT-DM (NCT06644651)
- Where
- Denmark
- Volunteers
- 314 people
- Sponsor
- Odense University Hospital
Coronary Artery Disease, CT Angiography
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography…
- Conditions
- Coronary Artery Disease, CT Angiography, PCSK9, Cardiovascular Events
- Trial name
- FLAVOUR IV (NCT06863545)
- Testing
- PCSK9 inhibitors and background lipid-modifying therapy, Standard lipid-modifying therapy
- Where
- 6 sites in China, South Korea
- Volunteers
- 3,596 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertension
Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan 160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to 40 mg/day in patients with moderate renal…
- Trial name
- NCT00140790
- Testing
- valsartan
- Where
- 2 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- Kumamoto University
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Ischemic Stroke
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.
- Trial name
- NCT06601127
- Testing
- Tiprogrel, Clopidogrel
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Coronary Artery Disease
Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events
Adventitial vasa vasorum (VV) as well as intraplaque microvessels are known to be associated with atherosclerotic plaque vulnerability. Contrast-enhanced ultrasound has been validated as a technique to measure the density of VV.
- Trial name
- NCT01436773
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Pittsburgh
Disc Disease, Instabilities Lumbar
Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment
Analyzing the impact of surgery and adverse events (AEs) on patients' well-being is of paramount importance as it provides essential information for benefit-risk assessment.
- Conditions
- Disc Disease, Instabilities Lumbar, Brain Tumor, Aneurysm
- Trial name
- NCT06352710
- Testing
- OP-Tracker App
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- Cantonal Hospital of St. Gallen
Hypertension
Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
The MAPEC study was designed to investigate whether normalizing the circadian blood pressure profile towards a more dipper pattern (increasing the diurnal/nocturnal ratio of blood pressure) by the use of Chronotherapy (that is…
- Trial name
- MAPEC (NCT00295542)
- Testing
- Ambulatory blood pressure monitoring, Chronotherapy, timing of antihypertensive medication, ACEI (including spirapril, enalapril, quinapril, lisinopril)
- Where
- Spain
- Volunteers
- 3,344 people, healthy volunteers welcome
- Sponsor
- University of Vigo
Coronary Disease, Fatty Acids, Unsaturated
123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients
The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.
- Conditions
- Coronary Disease, Fatty Acids, Unsaturated, Radioisotopes, Hemodialysis
- Trial name
- B-SAFE (NCT00586950)
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Colchicine, ICH - Intracerebral Hemorrhage
Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies.
- Conditions
- Colchicine, ICH - Intracerebral Hemorrhage, Stroke, Dependence
- Trial name
- CoVasc-ICH2 (NCT06587737)
- Testing
- Colchicine 0.5 MG
- Volunteers
- 1,125 people
- Sponsor
- Population Health Research Institute
Coronary Artery Disease
Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients (CORO-CTAIOMICS)
CAD is a leading cause of mortality in Europe. cCTA is recommended to rule out obstructive CAD, but, in most patients, it shows non-obstructive CAD.
- Trial name
- CORO-CTAIOMICS (NCT06029777)
- Where
- Italy
- Volunteers
- 2,190 people
- Sponsor
- IRCCS San Raffaele
Toxicity Due to Chemotherapy, Cardiovascular Morbidity
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown.
- Conditions
- Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related
- Trial name
- InvestiCAT (NCT03199300)
- Testing
- Anthracyclines, Trastuzumab, Cisplatin
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Atrial Fibrillation
Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients
SAFE-LAAC CKD Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device in patients with the end-stage renal…
- Trial name
- SAFE LAAC CKD (NCT05660811)
- Testing
- short postimplantation dual antiplatelet therapy, extended postimplantation dual antiplatelet therapy, long-term treatment with a single antiplatelet agent
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.